In this episode of Science Lab, we break down the latest research comparing traditional cigarette smoking with heated tobacco products (HTPs). Using evidence from multiple clinical studies, she explains how switching completely from smoking to HTPs affects biomarkers of exposure, biomarkers of potential harm, reported symptoms, and overall risk profiles.
All content for GFN News is the property of GFN.TV and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode of Science Lab, we break down the latest research comparing traditional cigarette smoking with heated tobacco products (HTPs). Using evidence from multiple clinical studies, she explains how switching completely from smoking to HTPs affects biomarkers of exposure, biomarkers of potential harm, reported symptoms, and overall risk profiles.
GFN News #164 | WHAT'S THE TRUTH ABOUT HARM REDUCTION IN NIGERIA?
GFN News
10 minutes 41 seconds
1 week ago
GFN News #164 | WHAT'S THE TRUTH ABOUT HARM REDUCTION IN NIGERIA?
Nigeria is experiencing increasing health impacts from smoking, and experts argue that harm reduction—not prohibition—is key to saving lives. In this GFN News episode, Joanna Junak interviews Uche Olatunji and Yusuf Adebisi on the major barriers to tobacco harm reduction in Nigeria, including widespread misinformation about nicotine and a lack of educational resources. They discuss community outreach, science-based alternatives, and the critical roles of universities and the media in shifting public perception. Learn how evidence-based harm-reduction strategies can help Nigerians make safer, informed decisions.
GFN News
In this episode of Science Lab, we break down the latest research comparing traditional cigarette smoking with heated tobacco products (HTPs). Using evidence from multiple clinical studies, she explains how switching completely from smoking to HTPs affects biomarkers of exposure, biomarkers of potential harm, reported symptoms, and overall risk profiles.